[Special Stock] Vibozone Pharm Rises on Approval News of Non-Narcotic Painkiller

Non-narcotic analgesic 'Eonapraju' (generic name Opiranjelin) has been approved as the 38th new drug, sending Bivobon Pharmaceutical's stock soaring to the upper limit.

As of 9:18 AM on the 13th, Bivobon Pharmaceutical is trading at 11,310 KRW, up 30% (2,610 KRW) from the previous trading day. The stock price of Bivobon Pharmaceutical rose to the price limit as soon as the market opened.

This is interpreted as a result of the news that Eonapraju, developed by Bivobon Pharmaceutical, has been approved as a new drug. On the same day, Bivobon Pharmaceutical announced that the non-narcotic analgesic Eonapraju (generic name Opiranjelin) had obtained marketing authorization from the Ministry of Food and Drug Safety.

This drug is used as a short-term therapy for moderate to severe acute pain control in adults after surgery. Opiranjelin is a non-narcotic analgesic in injectable form used to relieve postoperative pain. It produces analgesic effects by simultaneously inhibiting glycine transporter type 2 (GlyT2) and serotonin receptor 2a (5HT2a), which are directly involved in the generation of pain signals in peripheral nociceptors such as skin, muscles, ligaments, and joints.

This content was produced with the assistance of AI translation services.